Aldara (Imiquimod)

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Feb 1, 2006 → Jan 1, 2007

About Aldara (Imiquimod)

Aldara (Imiquimod) is a phase 3 stage product being developed by Viatris for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00294320. Target conditions include Actinic Keratosis.

What happened to similar drugs?

7 of 20 similar drugs in Actinic Keratosis were approved

Approved (7) Terminated (1) Active (13)
fluorouracil cream 0.5%SanofiApproved
Imiquimod + DiclofenacViatrisApproved
Imiquimod + DiclofenacViatrisApproved
Tirbanibulin 2.5 mg ointmentAlmirallApproved
TirbanibulinAlmirallApproved
Ameluz 10% Topical GelBiofronteraApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00294320Phase 3Completed

Competing Products

20 competing products in Actinic Keratosis

See all competitors